Alexandra Lainé1, Travis T Sims2, Olivia Le Saux3, Isabelle Ray-Coquard3, Robert L Coleman4. 1. Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France. alexandra.laine2@lyon.unicancer.fr. 2. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France. 4. Gynecologic Oncology, US Oncology Research, The Woodlands, TX, USA.
Abstract
PURPOSE OF REVIEW: Although the survival rate of patients with ovarian cancer (OC) has significantly improved, OC is still one of the most common causes of gynecologic cancer death in women worldwide. The current advances in primary treatment are based on recent regulatory approvals and recurrency of such treatments, challenging the development of a unified approach to care. Herein, we examine how integration of these new approaches is applied to patient's treatment. RECENT FINDINGS: We and others have recently reported clinical trials using bevacizumab and/or inhibitors of Poly (ADP-ribose) polymerase (PARP), which have greatly affected the change in first-line treatments for OC. As first-line therapy has evolved, therapeutic agents once designated for recurrent disease are increasingly being incorporated, changing our standard of care following previously indexed trials. Here, we provide an overview of the current treatment for OC patients, and we highlight practice patterns in Europe and in the USA with corresponding opinions on current and future treatments for platinum-sensitive recurrent OC.
PURPOSE OF REVIEW: Although the survival rate of patients with ovarian cancer (OC) has significantly improved, OC is still one of the most common causes of gynecologic cancer death in women worldwide. The current advances in primary treatment are based on recent regulatory approvals and recurrency of such treatments, challenging the development of a unified approach to care. Herein, we examine how integration of these new approaches is applied to patient's treatment. RECENT FINDINGS: We and others have recently reported clinical trials using bevacizumab and/or inhibitors of Poly (ADP-ribose) polymerase (PARP), which have greatly affected the change in first-line treatments for OC. As first-line therapy has evolved, therapeutic agents once designated for recurrent disease are increasingly being incorporated, changing our standard of care following previously indexed trials. Here, we provide an overview of the current treatment for OC patients, and we highlight practice patterns in Europe and in the USA with corresponding opinions on current and future treatments for platinum-sensitive recurrent OC.
Authors: Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum Journal: J Clin Oncol Date: 2012-04-23 Impact factor: 44.544
Authors: Krishnansu S Tewari; Robert A Burger; Danielle Enserro; Barbara M Norquist; Elizabeth M Swisher; Mark F Brady; Michael A Bookman; Gini F Fleming; Helen Huang; Howard D Homesley; Jeffrey M Fowler; Benjamin E Greer; Matthew Boente; Sharon X Liang; Chenglin Ye; Carlos Bais; Leslie M Randall; John K Chan; J Stuart Ferriss; Robert L Coleman; Carol Aghajanian; Thomas J Herzog; Philip J DiSaia; Larry J Copeland; Robert S Mannel; Michael J Birrer; Bradley J Monk Journal: J Clin Oncol Date: 2019-06-19 Impact factor: 44.544
Authors: John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk Journal: N Engl J Med Date: 2016-02-25 Impact factor: 91.245
Authors: Inga Bekes; Thomas W P Friedl; Tanja Köhler; Volker Möbus; Wolfgang Janni; Achim Wöckel; Christine Wulff Journal: Mol Cancer Date: 2016-02-12 Impact factor: 27.401
Authors: Amit M Oza; Adrian D Cook; Jacobus Pfisterer; Andrew Embleton; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Tjoung-Won Park-Simon; Gordon Rustin; Florence Joly; Mansoor R Mirza; Marie Plante; Michael Quinn; Andrés Poveda; Gordon C Jayson; Dan Stark; Ann Marie Swart; Laura Farrelly; Richard Kaplan; Mahesh K B Parmar; Timothy J Perren Journal: Lancet Oncol Date: 2015-06-23 Impact factor: 41.316